

Date: 07/12/2022

To
Department of Corporate Services,
BSE Limited,
Floor 25, P J Tower,
Dalal Street,
Mumbai - 400001.

Scrip Code: 526445

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015- Acquisition of a company by IBL Healthcare Limited, a wholly owned subsidiary of Indrayani Biotech Limited.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we are glad to inform that M/S IBL Healthcare Limited, a wholly owned subsidiary has acquired 5,10,000 equity shares, constituting 51% of total no of equity shares, of M/S Healthway India Private Limited (“HIPL”) (CIN: U74900TN2013PTC091433). Thus, HIPL has become a subsidiary company of IBL Healthcare Limited.

A Brief note of M/s Healthway India Private Limited is given in Annexure I.

The details of acquisition are given in Annexure II.

We request you to take this on your record.

Thanking you,

For Indrayani Biotech Limited

Swaminathan
Director
DIN: 02481041

ANNEXURE I - Brief about Healthway India Private Limited



Healthway

- Healthway India Private Limited (“Healthway”) was established in 2013 as a Health and Wellness company with a vision of Healing Lives.
- Healthway is a pharma and medical devices marketing company with its registered office at No.1 Milk Colony Road, Madhavaram Chennai, 600060, under the management of Mr. S. Madhavan.
- Healthway is marketing branded medicines and medical devices through ethical promotion to medical practitioners, Nursing Homes, clinics and leading corporate hospitals.
- Healthway has over 400 distributors and wholesalers all over South India catering to 20,000 clinics, nursing homes, corporate hospitals and pharmacies with a turnover of INR 45.5 million during FY 21-22.
- Healthway’s R&D establishment has assisted the development & Marketing of Onco Nutrition products (CELNORM), Ayurvedic Arthritis Liniment (ARLIN), GI – remedy for diarrhea (Loparet), Herbal cough syrup (HERCOF) and a unique delivery of Paracetamol, ready for the market.
- The aggregation with IBL Healthcare Limited will enable and expand capability to Research, launch and market Products under the brand name “Healthway” in Allopathy, Ayurveda and Nutraceuticals domains. The subsidiary will use the facilities and factory of associated Pharma manufacturing Companies with 40 years expertise in manufacturing quality medicines. The company is poised to assist medical practitioners with Quality Medicines, enable them heal millions of patients and reach a turnover of INR 300 million in the next two years.



About S. Madhavan

S. Madhavan is a hard-core pharma professional with more than 34 years of field experience as a Profit Centre Head of Healthway, Pearl Lifesciences – Muthu Pharmacy Group, Medtronic USA, St. Jude Medical USA, Alkem Laboratories and CIPLA Ltd.

S. Madhavan is a B.Sc. Chemistry graduate, MA (Administration) PGDMM - Post Graduate Diploma in Marketing, PGDCA Computer Applications and PGRM Retail Management.

S. Madhavan has vast expertise in reaching more than 40,000 Pharmacy retail stores and 400 Distribution channel partners enabling 10,000 Doctors to access quality medicine for their patients.

Annexure II

Details with respect to the acquisition as required under Regulation 30(6) read with Schedule III, Part A, Para A (1) of the SEBI Listing Regulations and the SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015

Acquisition of a company in India:

| | |
|---|--|
| Name of the target entity, details in brief such as size, turnover etc., | Healthway India Private Limited |
| Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | The transaction is at arm's length. There are no related parties involved in the transaction. |
| Industry to which the entity being acquired belongs; | Healthcare |
| Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | The company is becoming a subsidiary to our Wholly owned subsidiary, IBL Healthcare Limited. The vertical creates an immense intrinsic value to the company. |
| Brief details of any governmental or regulatory approvals required for the acquisition | NA |
| Indicative time period for completion of the acquisition; | On or before December 07, 2022. |
| Nature of consideration - whether cash consideration or share swap and details of the same; | Cash Consideration. |
| Cost of acquisition or the price at which the shares are acquired; | Rs. 5,10,000/- |
| Percentage of shareholding /control acquired and / or number of shares acquired | Percentage of holding: 51% No. of equity shares: 5,10,000 |
| Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | Date of incorporation: 31/05/2013 Turnover for past 3 years FY 21-22: Rs. 4,55,05,309/- FY 20-21: Rs. 1,08,65,407/- FY 19-20: Rs. 2,23,45,926/- The company is incorporated and existing in India |